OverviewSuggest Edit
Numab Therapeutics is an oncology-focused biopharmaceutical company. It develops multispecific antibody-based immunotherapies. The company provides a platform that reduces the random nature of the discovery process to yield multispecific biotherapeutics for chronic inflammation and cancer.
| Type | Private | |
| Founded | 2011 | |
| HQ | Wädenswil, CH | Map |
| Website | numab.com |
Latest Updates
| Employees (est.) (May 2022) | 58 | (+6%) |
| Cybersecurity rating | A | More |
Key People/Management at Numab
David Urech
Chief Executive Officer, Board Member
Oliver Middendorp
Chief Business Officer, Board Member
Peter Lichtlen
Chief Medical Officer, Board Member
Sebastian Meyer
Chief Operating Officer
Roland Helfenstein
Chief Financial Officer
Daniel Snell
VP Translational Sciences
Numab Office Locations
Numab has an office in Wädenswil
Wädenswil, CH (HQ)
Einsiedlerstrasse 34
Numab Financials and Metrics
Summary Metrics
Founding Date | 2011 |
Numab total Funding | $132.3 m |
Numab latest funding size | $110 m |
Time since last funding | a year ago |
Numab investors | BlackRock, Mitsubishi UFJ Capital, HBM Partners, RTW Investments, Novo Holdings, 3sbio, Cormorant, Forbion, BVF Partners, Eisai, Octagon Capital Advisors |
Numab's latest funding round in May 2021 was reported to be $110 m. In total, Numab has raised $132.3 m
Numab Cybersecurity Score
Numab Online and Social Media Presence
123 Twitter followers
Numab has 123 Twitter Followers. The number of followers has increased 1.7% month over month and increased 5% quarter over quarter
Numab's Trends
Numab News and Updates
May 20, 2021
Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics
COPENHAGEN, Denmark, May 20, 2021 /PRNewswire/ -- Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion...
Numab Frequently Asked Questions
When was Numab founded?
Numab was founded in 2011.
Who are Numab key executives?
Numab's key executives are David Urech, Oliver Middendorp and Peter Lichtlen.
How many employees does Numab have?
Numab has 58 employees.
Who are Numab competitors?
Competitors of Numab include Calidi Biotherapeutics, Cybrexa Therapeutics and Bexion Pharmaceuticals.
Where is Numab headquarters?
Numab headquarters is located at Einsiedlerstrasse 34, Wädenswil.
Where are Numab offices?
Numab has an office in Wädenswil.
How many offices does Numab have?
Numab has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies